GlassScriptPhysician profile
Joseph M Wildman
NPI 1114995941
$3,995.68
in general payments reported to CMS, 2019-2025
38 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $628 · 2021: $981 · 2022: $501 · 2023: $473 · 2024: $243 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.68 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $601.24 | 2019-2025 | Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $375.23 | 2019-2022 | |
| Genzyme Corporation | $364.58 | 2019-2021 | |
| Janssen Biotech, INC. | $294.92 | 2020-2025 | Rybrevant |
| Gilead Sciences, INC. | $263.44 | 2022-2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $195.63 | 2019-2023 | Zerbaxa, Dificid |
| Novartis Pharmaceuticals Corporation | $178.13 | 2019-2023 | |
| Novo Nordisk INC | $152.80 | 2019-2025 | |
| Abbvie INC. | $150.89 | 2021-2024 | Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $134.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.00 | 2019-2024 | |
| Lilly USA, LLC | $97.03 | 2019-2020 | |
| Celgene Corporation | $80.18 | 2019-2023 | Reblozyl |
| Pharmaessentia USA Corporation | $76.44 | 2023-2024 | Besremi |
| Takeda Pharmaceuticals U.S.A., INC. | $74.16 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.24 | 2019-2024 | |
| Agios Pharmaceuticals, INC. | $70.15 | 2020-2025 | Pyrukynd |
| Janssen Pharmaceuticals, INC | $69.52 | 2019-2021 | |
| Eisai INC. | $63.52 | 2019-2020 | |
| Genentech USA, INC. | $57.57 | 2019 | |
| Incyte Corporation | $54.44 | 2019-2022 | |
| Bausch Health US, LLC | $49.53 | 2025 | Wellbutrin |
| Rigel Pharmaceuticals, INC. | $46.06 | 2019-2022 | |
| Tg Therapeutics, INC. | $42.01 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $37.94 | 2020 | |
| Kite Pharma, INC. | $33.31 | 2025 | Yescarta |
| Macrogenics, INC. | $31.91 | 2022 | |
| Exelixis INC. | $29.90 | 2019 | |
| Exact Sciences Corporation | $27.66 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.10 | 2020-2021 | |
| Adaptive Biotechnologies Corporation | $19.62 | 2024 | Clonoseq |
| Alnylam Pharmaceuticals INC. | $17.34 | 2020 | |
| Roche Diagnostics Corporation | $15.35 | 2019 | |
| Amgen INC. | $14.77 | 2019 | |
| Array Biopharma INC | $14.57 | 2019 | |
| Blueprint Medicines Corporation | $14.57 | 2023 | Ayvakit |
| Puma Biotechnology, INC. | $14.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wildman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.